VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Friday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $2.50 price target on shares of VolitionRx in a research report on Wednesday, March 27th.

VolitionRx Stock Up 11.3 %

Shares of NYSE VNRX opened at $0.89 on Friday. VolitionRx has a 52 week low of $0.55 and a 52 week high of $2.10. The business has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $0.84. The company has a market cap of $73.05 million, a P/E ratio of -1.75 and a beta of 1.35.

VolitionRx (NYSE:VNRX) last issued its earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million. Equities research analysts anticipate that VolitionRx will post -0.4 EPS for the current year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent reporting period. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.